Vanguard Group Inc. Boosts Stock Holdings in Omeros Corporation $OMER

Vanguard Group Inc. grew its holdings in Omeros Corporation (NASDAQ:OMER) by 19.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,013,315 shares of the biopharmaceutical company’s stock after acquiring an additional 666,357 shares during the period. Vanguard Group Inc. owned about 0.06% of Omeros worth $68,929,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Farther Finance Advisors LLC grew its stake in shares of Omeros by 16.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 1,004 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Omeros by 113.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 5,677 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of Omeros in the 2nd quarter worth $32,000. Tower Research Capital LLC TRC grew its stake in shares of Omeros by 829.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 11,971 shares in the last quarter. Finally, Sei Investments Co. purchased a new position in shares of Omeros in the 2nd quarter worth $40,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OMER has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research note on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Omeros in a research note on Thursday. Wall Street Zen cut shares of Omeros from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. Zacks Research raised shares of Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. Finally, D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Omeros has a consensus rating of “Moderate Buy” and an average price target of $40.33.

Omeros Trading Down 7.6%

OMER stock opened at $13.28 on Friday. Omeros Corporation has a 12 month low of $2.95 and a 12 month high of $17.65. The company has a 50-day moving average price of $12.25 and a 200 day moving average price of $11.39. The stock has a market cap of $958.42 million, a PE ratio of 18.97 and a beta of 2.66.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.16. The company had revenue of $9.89 million for the quarter, compared to the consensus estimate of $4.19 million. Sell-side analysts forecast that Omeros Corporation will post -1.54 EPS for the current year.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.